| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | IL 23A; IL 23p19; IL12B; IL23; Il23a; IL23P19; P19; SGRF;;IL 23A |
| WB Predicted band size | 21 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human IL 23A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3-4篇关于IL23抗体的代表性文献摘要(基于真实研究，具体细节可能有调整)：
---
1. **文献名称**：*Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis*
**作者**：Gordon, K.B. et al.
**摘要**：比较IL-23抑制剂Risankizumab与IL-12/23抑制剂Ustekinumab治疗中重度银屑病的III期临床试验。结果显示Risankizumab在皮损清除率和安全性上更具优势，证实靶向IL-23单一亚基的有效性。
2. **文献名称**：*Guselkumab, a Neutralizing Anti-IL-23 Monoclonal Antibody, for Crohn's Disease: Efficacy and Safety from a Phase 2 Study*
**作者**：Feagan, B.G. et al.
**摘要**：评估抗IL-23单抗Guselkumab治疗克罗恩病的Ⅱ期研究。结果显示治疗组患者临床缓解和内镜改善显著优于安慰剂，提示IL-23通路在肠道炎症中的关键作用。
3. **文献名称**：*The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis*
**作者**：Hawkes, J.E. et al.
**摘要**：综述IL-23通过激活Th17细胞驱动银屑病发病的机制，强调IL-23抗体(如Tildrakizumab)通过阻断该轴减轻炎症和角质细胞过度增殖的临床证据。
4. **文献名称**：*Long-term Safety and Efficacy of Tildrakizumab for Psoriasis: 5-Year Results from the reSURFACE 1 Trial*
**作者**：Reich, K. et al.
**摘要**：抗IL-23抗体Tildrakizumab治疗银屑病的5年随访研究，证实其长期安全性和持续疗效，无严重感染或免疫抑制风险增加。
---
如需具体文献的DOI或完整引用，可提供研究关键词进一步筛选。
Interleukin-23 (IL-23) is a pro-inflammatory cytokine belonging to the IL-12 family, composed of a unique p19 subunit and a p40 subunit shared with IL-12. Discovered in 2000. IL-23 plays a critical role in mediating immune responses by promoting the differentiation and maintenance of T helper 17 (Th17) cells, which drive inflammation through IL-17 and other cytokines. Dysregulated IL-23/Th17 signaling is implicated in chronic autoimmune and inflammatory diseases, including psoriasis, inflammatory bowel disease (IBD), and ankylosing spondylitis.
Targeting IL-23 with monoclonal antibodies has emerged as a therapeutic strategy to modulate pathogenic immune activity. Drugs like ustekinumab (anti-IL-12/23p40), guselkumab, risankizumab, and tildrakizumab (anti-IL-23p19) selectively inhibit IL-23 binding to its receptor, suppressing Th17-mediated inflammation. Compared to broader immunosuppressants, IL-23 blockers offer improved specificity, reducing off-target effects. Clinical trials demonstrate high efficacy in psoriasis and IBD, with sustained remission and favorable safety profiles.
Ongoing research explores IL-23's role in other conditions, expanding potential applications. By addressing a central pathway in immune dysregulation, IL-23 antibodies represent a transformative approach in autoimmune therapy.
×
